FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914573062> ?p ?o ?g. }

• W2914573062 endingPage "S424" @default.
• W2914573062 startingPage "S423" @default.
• W2914573062 abstract "Introduction: Vedolizumab, a gut-selective antibody to α4β7 integrin, received FDA approval in May 2014 for the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). While integrated safety data from 6 trials of vedolizumab found low incidence of serious infections, there has yet to be published reports of infectious complications in an immunosuppressed population. Methods: Retrospective analysis of all patients with inflammatory bowel disease (IBD) who underwent liver transplant for primary sclerosing cholangitis (PSC) was performed. Patients exposed to vedolizumab post-liver transplant for the treatment of UC or CD were included. Data collected included patient demographics, IBD characteristics, vedolizumab treatment and duration, immunosuppression regimens for prevention of liver rejection, and infectious complications during vedolizumab therapy. Results: A total of 9 patients (6 UC, 3 CD) were included (Table 1). Eight (89%) were male; median age was 51 years (IQR 42 to 57). Indication for liver transplantation was PSC (n=6) or PSC-related cholangiocarcinoma (n=3). Patients were most commonly on tacrolimus (n=8, 89%) with or without prednisone (n=4, 67%) for prevention of rejection. Vedolizumab was initiated a median of 6 years (IQR 2-12 years) following liver transplantation. Patients had a median exposure time of 5 months (IQR 4.5-11.5 months) to vedolizumab at the time of data collection; the majority of patients (n=6, 67%) were on maintenance therapy as defined by receiving > 4 doses. Concurrent use of steroids and immunomodulator was 33% (n=3) and 0%, respectively. During exposure to vedolizumab, 6 patients (67%) experienced a total of 11 infections (Table 2): acute cholangitis (n=2, 4 infections), Clostridium difficile infection (n=2, 2 infections), and 5 other infections each with one occurrence. Three patients experienced infections that required four hospitalizations and one surgery: acute cholangitis requiring common bile duct stent placement (1) and ERCP for stent exchange (1), C. difficile infection requiring intravenous antibiotics, and a small bowel perforation with resultant fecal peritonitis and intra-abdominal abscess requiring surgical repair of perforation drainage of abscesses.Table: Table. Baseline characteristics of individuals with inflammatory bowel disease post-liver transplant on vedolizumabTable: Table. Infections in individuals with inflammatory bowel disease post-liver transplant on vedolizumabConclusion: Two-thirds of immunosuppressed IBD patients in our cohort of post-liver transplant individuals experienced infectious complications after initiation of vedolizumab. Larger case-control studies are needed to assess the risk of infectious complications in IBD patients receiving concurrent immunosuppressive therapy." @default.
• W2914573062 created "2019-02-21" @default.
• W2914573062 creator A5021713245 @default.
• W2914573062 creator A5046755536 @default.
• W2914573062 creator A5056735741 @default.
• W2914573062 creator A5067836692 @default.
• W2914573062 date "2017-10-01" @default.
• W2914573062 modified "2023-09-26" @default.
• W2914573062 title "Infectious Complications in Liver Transplant Patients Exposed to Vedolizumab for the Treatment of Inflammatory Bowel Disease" @default.
• W2914573062 doi "https://doi.org/10.14309/00000434-201710001-00759" @default.
• W2914573062 hasPublicationYear "2017" @default.
• W2914573062 type Work @default.
• W2914573062 sameAs 2914573062 @default.
• W2914573062 citedByCount "0" @default.
• W2914573062 crossrefType "journal-article" @default.
• W2914573062 hasAuthorship W2914573062A5021713245 @default.
• W2914573062 hasAuthorship W2914573062A5046755536 @default.
• W2914573062 hasAuthorship W2914573062A5056735741 @default.
• W2914573062 hasAuthorship W2914573062A5067836692 @default.
• W2914573062 hasConcept C126322002 @default.
• W2914573062 hasConcept C2776207728 @default.
• W2914573062 hasConcept C2776760755 @default.
• W2914573062 hasConcept C2778260677 @default.
• W2914573062 hasConcept C2778720950 @default.
• W2914573062 hasConcept C2779134260 @default.
• W2914573062 hasConcept C2779609443 @default.
• W2914573062 hasConcept C2780252810 @default.
• W2914573062 hasConcept C2780479503 @default.
• W2914573062 hasConcept C2909675724 @default.
• W2914573062 hasConcept C2911091166 @default.
• W2914573062 hasConcept C71924100 @default.
• W2914573062 hasConcept C90924648 @default.
• W2914573062 hasConceptScore W2914573062C126322002 @default.
• W2914573062 hasConceptScore W2914573062C2776207728 @default.
• W2914573062 hasConceptScore W2914573062C2776760755 @default.
• W2914573062 hasConceptScore W2914573062C2778260677 @default.
• W2914573062 hasConceptScore W2914573062C2778720950 @default.
• W2914573062 hasConceptScore W2914573062C2779134260 @default.
• W2914573062 hasConceptScore W2914573062C2779609443 @default.
• W2914573062 hasConceptScore W2914573062C2780252810 @default.
• W2914573062 hasConceptScore W2914573062C2780479503 @default.
• W2914573062 hasConceptScore W2914573062C2909675724 @default.
• W2914573062 hasConceptScore W2914573062C2911091166 @default.
• W2914573062 hasConceptScore W2914573062C71924100 @default.
• W2914573062 hasConceptScore W2914573062C90924648 @default.
• W2914573062 hasLocation W29145730621 @default.
• W2914573062 hasOpenAccess W2914573062 @default.
• W2914573062 hasPrimaryLocation W29145730621 @default.
• W2914573062 hasRelatedWork W2012436618 @default.
• W2914573062 hasRelatedWork W2023804846 @default.
• W2914573062 hasRelatedWork W203984136 @default.
• W2914573062 hasRelatedWork W2050886412 @default.
• W2914573062 hasRelatedWork W2076972568 @default.
• W2914573062 hasRelatedWork W2093877097 @default.
• W2914573062 hasRelatedWork W2170708782 @default.
• W2914573062 hasRelatedWork W2397635558 @default.
• W2914573062 hasRelatedWork W2575635931 @default.
• W2914573062 hasRelatedWork W2794344940 @default.
• W2914573062 hasVolume "112" @default.
• W2914573062 isParatext "false" @default.
• W2914573062 isRetracted "false" @default.
• W2914573062 magId "2914573062" @default.
• W2914573062 workType "article" @default.